Skip to main content
Hyper Corporation Inc. logo

Hyper Corporation Inc. — Investor Relations & Filings

Ticker · 065650 ISIN · KR7065650004 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 391 across all filing types
Latest filing 2021-03-22 Annual Report
Country KR South Korea
Listing KO 065650

About Hyper Corporation Inc.

https://hyper-corp.com/

Hyper Corporation Inc. is a company transitioning from a clinical-stage biopharmaceutical firm to a new-tech-based platform provider. Its core Bio & Healthcare division develops treatments and diagnostic technologies for neurodegenerative diseases like Alzheimer's, aiming to build a comprehensive digital senior healthcare platform. The company is expanding by integrating AI and blockchain technologies into new sectors. Its IP & Content division focuses on securing intellectual property and innovating content distribution, while its New Tech division develops platforms to connect online and offline services. This strategy fuses its biotechnology expertise with advanced IT to create new business models and services.

Recent filings

Filing Released Lang Actions
사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2020 (Jan 1, 2020 to Dec 31, 2020) submitted to the Financial Services Commission and the Korea Exchange. It contains comprehensive company information, financial data, management discussion, and governance details. In the context of Korean regulatory filings (DART system), this is the standard annual filing equivalent to a 10-K. FY 2020
2021-03-22 Korean
기타경영사항(특허권취득)(자율공시)(N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from a Korean company (Medipron) regarding the acquisition of a patent. It follows the standard format for 'Other Management Matters' (기타 경영사항) filings in the Korean market, which are used for material events that do not fall into specific financial reporting categories. Since it is a general regulatory announcement regarding a corporate event (patent acquisition) and does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a Regulatory Filing (RNS).
2021-03-17 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a short regulatory filing (under 601 characters) titled '주주총회 집중일 개최 사유 신고' (Report on the reason for holding a general meeting on a concentrated date). It explains why the company is holding its Annual General Meeting on a date that coincides with other companies' meetings, which is a standard regulatory disclosure requirement in the Korean market. Since it does not contain the full meeting materials or proxy statements, but rather serves as a specific regulatory notification, it falls under the general regulatory filing category.
2021-03-09 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Medifron DBT. It contains the meeting date, location, agenda items (financial statement approval, director appointments, etc.), and information regarding electronic voting and proxy solicitation. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and request their participation/votes. In the context of the provided categories, this fits the 'Proxy Solicitation & Information Statement' (PSI) classification.
2021-03-09 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy/Voting Rights). It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures (electronic/written), and proxy solicitation details. While it includes financial statements, these are provided as part of the meeting agenda and reference materials for shareholders to exercise their voting rights, which is characteristic of a Proxy Solicitation & Information Statement (PSI).
2021-03-09 Korean
[기재정정]합병등종료보고서(합병)
M&A Activity Classification · 100% confidence The document is a 'Merger Completion Report' (합병등종료보고서) filed by Medifron DBT. It details the finalization of a merger with SJ Core, including the timeline, creditor protection, and financial impact. In the context of corporate filings, documents related to M&A activity, including completion reports, are classified under the M&A Activity category.
2021-03-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.